Purpose:
In this study, hemostatic efficacy of Ankaferd Blood Stopper (ABS), a new
generation hemostatic agent, was compared in the presence of heparin
effect.
Methods:
Forty-eight Wistar albino rats were divided into two main groups as
heparinized and nonheparinized, and these two main groupswere divided into
six subgroups as control, Surgicel and ABS (n = 8). Grade 2 liver injury was
performed on rats as standard. All groups were compared in terms of weight,
laceration surface area, prothrombin time (PT), activated partial
thromboplastin time (aPTT), international normalized ratio (INR), bleeding
time, bleeding amount, hemoglobin (Hb) levels, macroscopic and microscopic
reactions to the agent used.
Results:
Whereas there was no statistically significant difference between weight,
laceration surface area, PT, INR and preoperative Hb values in the
heparinized and nonheparinized groups, postoperative Hb, bleeding time,
bleeding amount and aPTT values were statistically different (p < 0.05).
In the heparin-hemostat interaction, the ABS group had the lowest bleeding
in the heparinized group in terms of the amount of bleeding compared to the
control and Surgicel groups (F = 0.764; p = 0.047). In macroscopic and
microscopic comparison, there was no difference between the groups in terms
of cell necrosis andfresh bleeding (p > 0.05), it was found that the
Surgicel group had statistical significantly higher reaction scores (p <
0.05) than the other groups in terms of other parameters.
Conclusions:
Ankaferd Blood Stopper can be safely and effectively used in surgical
practice and in patients with additional diseases requiring heparinization,
since it causes minimal reaction in the liver and decreases the amount of
bleeding especially in the heparinized group.